Dr. Alisha Pike Kirby, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4180 Highway 431, Roanoke, AL 36274 Phone: 334-863-6148 Fax: 334-863-6213 |
James Thomas Wood, RPH, CDE Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3868 Highway 431, Roanoke, AL 36274 Phone: 334-863-7511 Fax: 334-863-7500 |
Monica Karen Terry, RPH, CDE Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3868 Highway 431, Roanoke, AL 36274 Phone: 334-863-7511 Fax: 334-863-7500 |
News Archive
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
Thomson Reuters today announced that BMJ Group has selected ScholarOne Manuscripts as the peer review workflow management system for all of its journals. BMJ Group publishes 33 leading specialist titles, and the British Medical Journal, one of the world's most influential and widely read journals.
Arrayit Corporation today announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies (CENAT) in Poznan, Poland. The Arrayit NanoPrint Microarrayer will be used by CENAT for scientific and medical collaborations throughout the prosperous democracy.
Fish and some amphibians possess a unique sensory capability in the so-called lateral-line system. It allows them, in effect, to "touch" objects in their surroundings without direct physical contact or to "see" in the dark. Professor Leo van Hermmen and his team in the physics department of the Technische Universitaet Muenchen are exploring the fundamental basis for this sensory system. What they discover might one day, through biomimetic engineering, better equip robots to orient themselves in their environments.
University of Virginia School of Medicine researchers have identified new insights and potential treatment approaches for muscle loss in myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy.
› Verified 2 days ago